Identification of abnormally high expression of POGZ as a new biomarker associated with a poor prognosis in osteosarcoma

https://doi.org/10.4081/ejh.2021.3264

Authors

  • Sikuan Zheng The Second Affiliated Hospital of Nanchang University; The Second Clinical Medical College of Nanchang University; Institute of Orthopedics of Jiangxi Province; Institute of Minimally Invasive Orthopedics of Nanchang University, China. https://orcid.org/0000-0002-3462-8547
  • Yue Liu Queen Mary School, Medical collage of Nanchang University, China. https://orcid.org/0000-0002-7623-4431
  • Haohe Sun The Second Clinical Medical College, Medical collage of Nanchang University, China. https://orcid.org/0000-0002-8967-302X
  • Jingyu Jia The Second Affiliated Hospital of Nanchang University; Institute of Orthopedics of Jiangxi Province; Institute of Minimally Invasive Orthopedics of Nanchang University, China.
  • Tianlong Wu The Second Affiliated Hospital of Nanchang University; The Second Clinical Medical College of Nanchang University; Institute of Orthopedics of Jiangxi Province; Institute of Minimally Invasive Orthopedics of Nanchang University, China. https://orcid.org/0000-0002-6105-1499
  • Rui Ding The Second Affiliated Hospital of Nanchang University; Institute of Orthopedics of Jiangxi Province; Institute of Minimally Invasive Orthopedics of Nanchang University, China. https://orcid.org/0000-0003-1936-064X
  • Xigao Cheng | 228206846@qq.com The Second Affiliated Hospital of Nanchang University; Institute of Orthopedics of Jiangxi Province; Institute of Minimally Invasive Orthopedics of Nanchang University, China. https://orcid.org/0000-0002-6105-1499

Abstract

Osteosarcoma (OS) is the most prevalent malignant bone tumor in children and young adults. There is an urgent need for a novel biomarker related to the prognosis of OS. We performed a meta-analysis incorporating six independent datasets and performed a survival analysis with one independent dataset GSE21257 in the GEO database for gene screening. The results revealed that one potential biomarker related to OS survival, POGZ was the most significantly upregulated gene. We also verified that the POGZ was overexpressed in clinical samples. The survival analysis revealed that POGZ is associated with a poor prognosis in OS. Moreover, flow cytometry analysis of isolated OS cells demonstrated that OS cells were arrested in the G1 phase after POGZ knockdown. The RNA-seq results indicated that POGZ was co-expressed with CCNE1 and CCNB1. Pathway analysis showed that genes associated with high expression levels of POGZ were related to the cell cycle pathway. A cell model was constructed to detect the effects of POGZ. After POGZ knockdown, OS cell proliferation, invasion and migration were all decreased. Therefore, POGZ is an important gene for evaluating the prognosis of OS patients and is a potential therapeutic target.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Li Y, Nakka M, Kelly AJ, Lau CC, Krailo M, Barkauskas DA, et al. p27 is a candidate prognostic biomarker and metastatic promoter in osteosarcoma. Cancer Res 2016;76:4002-11. DOI: https://doi.org/10.1158/0008-5472.CAN-15-3189

Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev Endocrinol 2017;13:480-91. DOI: https://doi.org/10.1038/nrendo.2017.16

Rickel K, Fang F, Tao J. Molecular genetics of osteosarcoma. Bone 2017;102:69-79. DOI: https://doi.org/10.1016/j.bone.2016.10.017

Tao T, Shen Q, Luo J, Xu Y, Liang W. MicroRNA-125a regulates cell proliferation via directly targeting E2F2 in osteosarcoma. Cell Physiol Biochem 2017;43:768-74. DOI: https://doi.org/10.1159/000481560

Yoshida A, Fujiwara T, Uotani K, Morita T, Kiyono M, Yokoo S, et al. Clinical and functional significance of intracellular and extracellular microRNA-25-3p in osteosarcoma. Acta Med Okayama 2018;72:165-74.

Ma C, Nie XG, Wang YL, Liu XH, Liang X, Zhou QL, et al. CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma. Mol Med Rep 2019;19:4205-12. DOI: https://doi.org/10.3892/mmr.2019.10104

Aran V, Devalle S, Meohas W, Heringer M, Cunha Caruso A, Pinheiro Aguiar D, et al. Osteosarcoma, chondrosarcoma and Ewing sarcoma: Clinical aspects, biomarker discovery and liquid biopsy. Crit Rev Oncol Hematol 2021;162:103340. DOI: https://doi.org/10.1016/j.critrevonc.2021.103340

Tian H, Zhou T, Chen H, Li C, Jiang Z, Lao L, et al. Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway. J Orthop Res 2019;37:1638-48. DOI: https://doi.org/10.1002/jor.24244

Petryszak R, Burdett T, Fiorelli B, Fonseca NA, Gonzalez-Porta M, Hastings E, et al. Expression Atlas update--a database of gene and transcript expression from microarray- and sequencing-based functional genomics experiments. Nucleic Acids Res 2014;42(Database issue):D926-32. DOI: https://doi.org/10.1093/nar/gkt1270

Han G, Wang Y, Bi W. C-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway. Oncol. Res 2012;20:149-56. DOI: https://doi.org/10.3727/096504012X13522227232237

Chen D, Zhao Z, Huang Z, Chen DC, Zhu XX, Wang YZ, et al. Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Res 2018;6:11. DOI: https://doi.org/10.1038/s41413-018-0009-8

Muff R, Ram Kumar RM, Botter SM, Born W, Fuchs B. Genes regulated in metastatic osteosarcoma: evaluation by microarray analysis in four human and two mouse cell line systems. Sarcoma 2012;2012:937506. DOI: https://doi.org/10.1155/2012/937506

Mohamed FEA, Khalil EZI, Toni NDM, Correction to: Caveolin-1 expression together with VEGF can be a predictor for lung metastasis and poor prognosis in osteosarcoma. Pathol Oncol Res 2020;26:2013-4. DOI: https://doi.org/10.1007/s12253-019-00790-2

Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol 2015;33:3029-35. DOI: https://doi.org/10.1200/JCO.2014.59.4895

Sadikovic B, Yoshimoto M, Al-Romaih K, Maire G, Zielenska M, Squire JA. In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS One 2008;3:e2834. DOI: https://doi.org/10.1371/journal.pone.0002834

Sadikovic B, Yoshimoto M, Chilton-MacNeill S, Thorner P, Squire JA, Zielenska M. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet 2009;18:1962-75. DOI: https://doi.org/10.1093/hmg/ddp117

Fritsche-Guenther R, Noske A, Ungethüm U, Kuban RJ, Schlag PM, Tunn PU, et al. De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathology 2010;57:836-50. DOI: https://doi.org/10.1111/j.1365-2559.2010.03713.x

Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009;10:625. DOI: https://doi.org/10.1186/1471-2164-10-625

Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, et al. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 2013;13:245. DOI: https://doi.org/10.1186/1471-2407-13-245

Kuijjer ML, van den Akker BE, Hilhorst R, Mommersteeg M, Buddingh EP, Serra M, et al. Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. BMC Med Genomics 2014;7:4. DOI: https://doi.org/10.1186/1755-8794-7-4

Buddingh EP, Ruslan SEN, Reijnders CMA, Szuhai K, Kuijjer ML, Roelofs H, et al. Mesenchymal stromal cells of osteosarcoma patients do not show evidence of neoplastic changes during long-term culture. Clin Sarcoma Res 2015;5:16. DOI: https://doi.org/10.1186/s13569-015-0031-1

Buddingh EP, Kuijjer ML, Duim RA, Bürger H, Agelopoulos K, Myklebost O, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res 2011;17:2110-9. DOI: https://doi.org/10.1158/1078-0432.CCR-10-2047

Azim HA Jr, Peccatori FA, Brohée S, Branstetter D, Loi S, Viale G, et al. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res 2015;17:24. DOI: https://doi.org/10.1186/s13058-015-0538-7

Ho XD, Phung P, Q Le V, H Nguyen V, Reimann E, Prans E, et al. Whole transcriptome analysis identifies differentially regulated networks between osteosarcoma and normal bone samples. Exp Biol Med (Maywood) 2017;242:1802-11. DOI: https://doi.org/10.1177/1535370217736512

Ho XD, Nguyen HG, Trinh LH, Reimann E, Prans E, Kõks G, et al. Analysis of the expression of repetitive DNA elements in osteosarcoma. Front Genet 2017;8:193. DOI: https://doi.org/10.3389/fgene.2017.00193

Nozawa RS, Nagao K, Masuda HT, Iwasaki O, Hirota T, Nozaki N, et al. Human POGZ modulates dissociation of HP1alpha from mitotic chromosome arms through Aurora B activation. Nat Cell Biol 2010;12:719-27. DOI: https://doi.org/10.1038/ncb2075

Ibaraki K, Hamada N, Iwamoto I, Ito H, Kawamura N, Morishita R, et al. Expression analyses of POGZ, a responsible gene for neurodevelopmental disorders, during mouse brain development. Dev Neurosci 2019;41:139-48. DOI: https://doi.org/10.1159/000502128

Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol 2019;29:212-26. DOI: https://doi.org/10.1016/j.tcb.2018.12.001

Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ 2018;25:114-32. DOI: https://doi.org/10.1038/cdd.2017.172

Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, Matsunoshita Y, et al. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 2009;100:1957-65. DOI: https://doi.org/10.1038/sj.bjc.6605060

Shen JH, Qu CB, Chu HK, Cui MY, Wang YL, Sun YX, et al. siRNA targeting TCTP suppresses osteosarcoma cell growth and induces apoptosis in vitro and in vivo. Biotechnol Appl Biochem 2016;63:5-14. DOI: https://doi.org/10.1002/bab.1335

Xie B, Wang S, Jiang N, Li JJ. Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance. Cancer Lett 2019;443:56-66. DOI: https://doi.org/10.1016/j.canlet.2018.11.019

Möröy T, Geisen C. Cyclin E. Int J Biochem Cell Biol 2004;36:1424-39. DOI: https://doi.org/10.1016/j.biocel.2003.12.005

Published
2021-09-03
Info
Issue
Section
Articles
Supporting Agencies
Natural Science Research Program of Jiangxi (No. 20202ACBL206012. to XC), National Natural Science Foundation of China (No. 81660357 to XC), National Natural Science Foundation of China (No. 81860397 to XC)
Keywords:
Prognosis, osteosarcoma, biomarkers, POGZ, cell cycle
Statistics
  • Abstract views: 169

  • PDF: 66
  • Supplementary: 4
  • HTML: 0
How to Cite
Zheng, S., Liu, Y., Sun, H., Jia, . J., Wu, T., Ding, R., & Cheng, X. (2021). Identification of abnormally high expression of POGZ as a new biomarker associated with a poor prognosis in osteosarcoma. European Journal of Histochemistry, 65(3). https://doi.org/10.4081/ejh.2021.3264